美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

HORIZON KINETICS MEDICAL ETF

34.99

+0.03280.09%

盤後：35.110.1145+0.33%16:10 EDT

成交量：428

成交額：1.51萬

市值：1,644.36萬

市盈率：- -

高：35.11

開：35.11

低：34.99

收：34.96

52周最高：37.90

52周最低：28.87

股本：46.99萬

流通股本：46.99萬

量比：0.32

換手率：0.09%

股息：0.41

股息率：1.17%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

強生股價盤前上漲1.2%，此前有報道稱阿波羅全球管理公司有意收購強生旗下骨科業務，潛在交易估值約為200億美元。

ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集機構看好創新藥投資機會

【券商聚焦】華創證券維持翰森製藥（03692）推薦評級指創新藥驅動業績增長

A股收評：創業板指震盪走低跌1.1%，培育鑽石、創新藥、MLCC概念板塊漲幅居前

樂高科技、艾迪爾等35家藥企涉商業賄賂，登上貴州醫保基金失信企業「黑榜」

創新藥闖關醫保

国际金融报

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

螞蟻集團入股醫療服務商風石健康

「超30家藥企長期行賄」，涉案醫院回應

A股午評：滬指低開高走漲0.16%，MLCC概念、創新藥、培育鑽石板塊表現活躍

醫療服務板塊走高，萬邦醫藥20cm漲停

強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期

強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。

創新藥企赴港IPO提速小分子創新藥成主力賽道

经济参考报

華泰證券：港股基本面與貼現率賽跑首選紅利及創新藥

B7-H3靶點ADC全球率先突破世界肺癌大會迎來中國時刻

中国新闻网

WCLC大會開幕！一文搞懂創新藥臨床指標

創新藥跌跌不休，什麼原因？華寶基金港股通創新藥ETF（520880）失守所有均線

情緒冰點，A股單周成交額創年內新低！有色領跌，創新藥不振！關注華寶基金創業板人工智能ETF

從「產品出海」到「體系出海」，上海創新藥企復宏漢霖加速全球佈局

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/MEDX/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":34.9905,"timestamp":1789588800000,"preClose":34.9577,"halted":0,"volume":428,"hourTrading":{"tag":"盘后","latestPrice":35.105,"preClose":34.9905,"latestTime":"16:10 EDT","volume":6,"amount":209.943,"timestamp":1789589404310,"change":0.1145,"changeRate":0.003272,"amplitude":0},"delay":0,"changeRate":0.0009382768317136027,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"已收盤","change":0.0328,"latestTime":"09-16 16:00:00 EDT","open":35.105,"high":35.105,"low":34.9905,"amount":15054,"amplitude":0.003275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.9577,"sharesOutstanding":569946,"nav":34.96,"aum":16429312.16,"dividendRate":0.011689,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.105,"preClose":34.9905,"latestTime":"16:10 EDT","volume":6,"amount":209.943,"timestamp":1789589404310,"change":0.1145,"changeRate":0.003272,"amplitude":0},"volumeRatio":0.317037},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.317037,"shares":469946,"dividePrice":0.409,"high":35.105,"amplitude":0.003275,"preClose":34.9577,"low":34.9905,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":34.9905,"eps":0,"divideRate":0.011689,"volume":428,"delay":0,"ttmEps":0,"open":35.105,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":35.2396,"twentyDayClose":36.4884,"sixtyDayClose":34.3915},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667659843","title":"強生股價盤前上漲1.2%，此前有報道稱阿波羅全球管理公司有意收購強生旗下骨科業務，潛在交易估值約為200億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667659843?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:18","pubTimestamp":1789373891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","PJP","IE00B42XCP33.USD","FTXH","AAUM","TRUH","FHLC","IE00BDGV0183.EUR","BK4184","LU1221951046.USD","IE0009355771.USD","LU0070217475.USD","LU2023250330.USD","MEDX","JNJ","IE000BZT7R73.USD","LU0320765646.SGD","LU1244550221.USD","LU2896262040.SGD","GDOC","LU0889566641.SGD","RXL","LU0345769128.USD","XLV","LU2592432038.USD","LBO","BMED","IXJ","GPZ","IE00BKVL7J92.USD","LU1430594728.SGD","IE00BN8TJ469.HKD","IE000WAW04H5.SGD","LU1032466523.USD","BK4559","LU1066053197.SGD","LU0882574055.USD","LU0289739343.SGD","LU0792757196.USD","VHT","LU1267930813.SGD","IYH","LU1066051225.USD","LU2430703251.USD","IHE","PRVT","LU0426412945.USD","APO","JDOC","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667554366","title":"ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集 機構看好創新藥投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554366?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华夏恒生生科涨超4%。截至发稿，涨4.01%，报15.58港元，成交额6924.78万港元。本次WCLC会议上，中国新药表现亮眼，入选口头报告研究19项，小型口头报告研究45项，刷新记录。国金证券称，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","LNGR","159992","FDN","03069","06978","BK4585","MEDX","BK1574","BK4550","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655868","title":"【券商聚焦】華創證券維持翰森製藥（03692）推薦評級 指創新藥驅動業績增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655868","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655868?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369287,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华创证券发布研报指，翰森制药 2026年上半年实现总营业收入83.04亿元人民币，创新药收入约70.92亿元，占总收入比例约85.4%创历史新高；净利润42.58亿元。研发管线方面，公司创新药临床试验超70项，候选创新药超40个。华创证券指，公司创新药收入驱动业绩稳健增长，BD出海持续推进，在研管线储备丰富，看好聚焦创新和国际化的战略布局。预计2026-2028年营收分别为165.12/185.22/209.34亿元人民币，同比增长9.9%/12.2%/13.0%；归母净利润为61.10/67.78/75.09亿元人民币。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","159992","161027","LNGR","KCE","03692","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667534816","title":"A股收評：創業板指震盪走低跌1.1%，培育鑽石、創新藥、MLCC概念板塊漲幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2667534816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667534816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369262,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MLCC","MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667536746","title":"樂高科技、艾迪爾等35家藥企涉商業賄賂，登上貴州醫保基金失信企業「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2667536746","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667536746?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:51","pubTimestamp":1789368717,"startTime":"0","endTime":"0","summary":"根据公告，对于配送企业，根据信用评价结果限制或中止配送企业在贵州省的配送资格1-5年；对于生产企业，除提醒告诫、提示风险外，限制或中止相关涉案产品或全部产品挂网、投标资格。据悉，贵州省医保基金运行服务中心给出了修复信用评级的方法。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789368658648386760","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["AGNG","BK1583","GDOC","BK1574","LNGR","MEDX","09996","IEIH","PTH","HART","MDEV","LGHT","BK1100","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653941","title":"創新藥闖關醫保","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653941","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:46","pubTimestamp":1789368365,"startTime":"0","endTime":"0","summary":"张力制图9月5日至8日，2026年国家基本医保药品目录现场谈判（下称“国谈”）竞价工作在北京开展，上百家国内外药企代表到场参与。本次共有124个目录外药品入围谈判竞价环节，肿瘤、罕见病、慢性病、儿童用药等社会关注度较高的创新药均在列，有望通过谈判纳入新版国家医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873368645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873368645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","MEDX","LNGR","159992","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","LU0455707207.USD","IE00B543WZ88.USD","IBBQ","BK1589","KURE","LU2476274720.SGD","LU0348767384.USD","LU2476274308.USD","01177","LU0244354667.USD","BK1191","LNGR","LU0348735423.USD","LU0348766576.USD","LU0417516738.SGD","MEDX","159992","LU0348827113.USD","HK0000165453.HKD","LU2488822045.USD","VXUS","LU1961090484.USD","LU2097828557.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348825331.USD","01530","KCAI","LU2778985437.USD","06978","BK1593","LU0607220059.USD","09926","LU1969619763.USD","LU0634319403.HKD","LU2097828805.USD","LU0326950275.SGD","LU1188198961.HKD","BK1574","BK1521","LU0561508036.HKD","BK4588","IE00BZ08YR35.GBP","01801","LU0348784397.USD","LU2097828714.EUR","BK1161","LU1831875114.USD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637017","title":"螞蟻集團入股醫療服務商風石健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637017","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637017?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:30","pubTimestamp":1789363802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863208","title":"「超30家藥企長期行賄」，涉案醫院回應","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863208","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667863208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:36","pubTimestamp":1789356960,"startTime":"0","endTime":"0","summary":"澎湃新闻首席记者 李潇潇9月13日，国家医保局发布《医疗机构涉医药购销商业贿赂案》一文提到，仅2025年下半年，河北医科大学第二医院就涉及9件司法刑事判决。在国家医保局9月13日最新披露的信息中，有超过30家医药企业长期对河北医科大学第二医院工作人员行贿。具体到河北祥恩医疗器械贸易有限公司一家，该公司为向河北医科大学第二医院销售价格虚高的医疗耗材，累计向该医院工作人员行贿2064万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HART","MDEV","GDOC","LGHT","BK1583","RSPH","BK1100","09996","MEDX","LNGR","PTH","BK1574","AGNG","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632818","title":"A股午評：滬指低開高走漲0.16%，MLCC概念、創新藥、培育鑽石板塊表現活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632818?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:31","pubTimestamp":1789356669,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","MLCC","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667634858","title":"醫療服務板塊走高，萬邦醫藥20cm漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2667634858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667634858?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:31","pubTimestamp":1789353086,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120093998","title":"強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120093998","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120093998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:47","pubTimestamp":1789350464,"startTime":"0","endTime":"0","summary":"强生公司日前公布了一项重磅临床数据——其旗下药物Rybrevant与化疗联用，在携带EGFR外显子20插入突变的非小细胞肺癌患者中，取得了目前公开报告中最长的中位总生存期。EGFR外显子20插入突变，历来被视为治疗难点，可选方案有限且疗效欠佳。观察人士指出，这不仅能巩固Rybrevant在精准医疗版图中的地位，更可能重塑晚期非小细胞肺癌的一线治疗格局。强生能否借此在竞争激烈的肺癌药物市场中进一步扩大优势，值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689431.USD","LU2456880835.USD","LU1244550494.USD","LU0345769631.USD","LU1121112475.USD","LU1629891620.HKD","IE00B7SZLL34.SGD","LU1778281490.HKD","IE00BSNM7G36.USD","LU0320765646.SGD","LU1066051498.USD","LU1066051811.HKD","LU2133065610.SGD","LU0289961442.SGD","SG9999002232.USD","IE000M9KFDE8.USD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU1196500208.SGD","IE000SO60NU8.SGD","BK4588","IE0034235303.USD","LU0545562505.USD","BMED","IE000WAW04H5.SGD","LU1430594728.SGD","BK4504","LU0210536198.USD","LU2471134523.USD","BK4533","BK4581","TRUH","LU2403377893.USD","LU2417539215.USD","LU1066051225.USD","LU2129689605.HKD","IE00BJJMRZ35.SGD","LU0795875169.SGD","LU1989771016.USD","IE00B19Z3581.USD","LU1929549753.HKD","LU1145028129.USD","LU1228905540.USD","IXJ","LU1057294990.SGD","JNJ","LU0994945656.USD","LU2213496289.HKD","LU0795875086.SGD","SG9999001440.SGD","IE00B2B36J28.USD","LU2430703095.HKD","LU1551013425.SGD","LU2756315318.SGD","LU0792757196.USD","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU0345769128.USD","LU1074936037.SGD","LU2487616109.SGD","LU0070217475.USD","LU1718418525.SGD","LU0640476718.USD","LU1032955483.USD","BK4007","IE00BLSP4239.USD","LU0057025933.USD","IE0002270589.USD","LU1674673428.USD","LU1244550221.USD","IE00BGHQF631.EUR","LU2023250330.USD","IE00BVYPNV92.GBP","LU0203345920.USD","LU1267930813.SGD","LU0466842654.USD","LU1221951129.SGD","IE000F7OJYX1.SGD","LU2756315664.SGD","LU0345770993.USD","LU0114720955.EUR","IE00B3PB1722.GBP","LU0426412945.USD","IE000MB6IJN5.SGD","SGXZ80539844.SGD","LU0820561818.USD","LU1674673691.USD","LU1914381329.SGD","LU2430703251.USD","LU2592432038.USD","LU0345770308.USD","LU1894683348.USD","LU0472753341.HKD","RXL","LU0689472784.USD","LU0124676726.USD","BK4550","LU0882574055.USD","SG9999001176.SGD","IE00BKVL7J92.USD","LU0426417589.USD","LU1244550577.SGD","LU1732800096.USD","IE00BBT3K403.USD","LU1162221912.USD","LU0122379950.USD","LU0964807845.USD","LU1221951046.USD","LU1059921491.USD","VHT","LU1506573853.SGD","IE000BZT7R73.USD","LU1061106388.HKD","LU2602419157.SGD","BK4534","IE00BN8TJ469.HKD","BK4585","IE00BDGV0183.EUR","LU0820561909.HKD","LU0069063385.USD","IE00BFTCPJ56.SGD","BK4532","SG9999013999.USD","LU0203347892.USD","LU1228905037.USD","BK4559","LU0098860793.USD","LU0787776722.HKD","LU1585245621.USD","LU2089984988.USD","MEDX","LU1935042991.SGD","LU0432979614.USD","IE00B1BXHZ80.USD","IE0001KFT4U8.USD","LU1032466523.USD","IYH","LU0820562030.AUD","LU1983299246.USD","LU0289739699.SGD","LU1894683264.USD","SGXZ57979304.SGD","LU0689626769.HKD","LU0053666078.USD","IE00BJT1NW94.SGD","LU0683600562.USD","IE00B42XCP33.USD","LU0889566641.SGD","LU0162691827.USD","LU2347655156.SGD","IE00B3T34201.USD","LU1043141123.HKD","JDOC","IE00BVYPNW00.USD","LU1066053197.SGD","LU0943347566.SGD","IHE","LU0058720904.USD","LU2468319806.SGD","LU1551013342.USD","FTXH","GDOC","IE0000B7K699.USD","LU0912757837.SGD","LU2471134879.HKD","LU0234570918.USD","LU1280957306.USD","LU1732799900.SGD","LU1496350502.SGD","LU2471134952.CNY","LU2505996681.GBP","LU1043141396.HKD","BK4568","LU0234572021.USD","FHLC","IE00BLSP4452.SGD","LU0289739343.SGD","LU0210528500.USD","IE0002141913.USD","LU2471134796.USD","XLV","SG9999001176.USD","LU2129689514.USD","LU2112291526.USD","LU2896262040.SGD","LU2505996509.AUD","LU1023059063.AUD","LU1261432733.SGD","LU2430703178.SGD","IE00B4R5TH58.HKD","LU2750360641.GBP","LU0985320562.USD","LU1291159041.SGD","BK4592","SG9999002224.SGD","LU0511384066.AUD","LU0072461881.USD","PJP","LU2750360997.AUD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631840","title":"強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631840?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:46","pubTimestamp":1789350398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IXJ","LU1145028129.USD","BK4550","IE00BLSP4239.USD","GDOC","LU0683600562.USD","LU0053666078.USD","BK4568","BMED","FHLC","LU0511384066.AUD","LU2471134523.USD","BK4559","FTXH","IE00BGHQF631.EUR","XLV","IE00BFTCPJ56.SGD","IYH","LU2471134879.HKD","MEDX","LU1244550494.USD","BK4533","IE00BDGV0183.EUR","LU0122379950.USD","TRUH","LU0985320562.USD","LU2133065610.SGD","JNJ","LU1032466523.USD","LU1674673691.USD","BK4588","LU0820561909.HKD","IHE","LU1894683264.USD","IE0002141913.USD","RXL","IE0000B7K699.USD","IE00BVYPNV92.GBP","PJP","IE0001KFT4U8.USD","IE00B3T34201.USD","LU2592432038.USD","LU1935042991.SGD","JDOC","LU2089984988.USD","LU2430703095.HKD","LU1280957306.USD","VHT","LU0426417589.USD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635798","title":"創新藥企赴港IPO提速 小分子創新藥成主力賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635798","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635798?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 07:52","pubTimestamp":1789343542,"startTime":"0","endTime":"0","summary":"【创新药企赴港IPO提速 小分子创新药成主力赛道】8月下旬以来，征祥医药、益方生物、迪哲医药、贝达药业、维眸生物、诺令生物、普莱医药、信立泰等多家企业，密集向港交所递交上市申请，掀起新一轮本土创新药闯关港股18A板块的热潮。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["LNGR","MEDX","KCE","159992","06978","FRHC","IBBQ","IPOS","BK1161","BK4127","BK1574","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667871386","title":"華泰證券：港股基本面與貼現率賽跑 首選紅利及創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2667871386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667871386?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 23:44","pubTimestamp":1789314266,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","KCAI","BK4588","IBBQ","BK4585","VXUS","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667682589","title":"B7-H3靶點ADC全球率先突破 世界肺癌大會迎來中國時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2667682589","media":"中国新闻网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667682589?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 20:11","pubTimestamp":1789301465,"startTime":"0","endTime":"0","summary":"9月13日，韩国首尔，世界肺癌大会(WCLC)主席论坛。中山大学肿瘤防治中心张力教授分享了B7-H3抗体偶联药物依康坦博妥塔单抗(Tam-Peli，代号YL201)对比盐酸托泊替康用于治疗复发性小细胞肺癌的Ⅲ期注册研究TAISHAN-302成果，这是全球范围内以B7-H3为靶点的ADC首次公布Ⅲ期临床研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872861815.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872861815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","IBBQ","BK1161","MEDX","LNGR","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667272684","title":"WCLC大會開幕！一文搞懂創新藥臨床指標","url":"https://stock-news.laohu8.com/highlight/detail?id=2667272684","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667272684?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:26","pubTimestamp":1789298760,"startTime":"0","endTime":"0","summary":"9月12日，2026年WCLC正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司公布旗下核心产品临床数据。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。文中提及个股在恒生港股通创新药精选指数中的权重占比情况见配图。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvw4447257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","IBBQ","BK1161","06978","159992","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667684274","title":"創新藥跌跌不休，什麼原因？華寶基金港股通創新藥ETF（520880）失守所有均線","url":"https://stock-news.laohu8.com/highlight/detail?id=2667684274","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667684274?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:25","pubTimestamp":1789298700,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝失守所有均线，重仓A股创新药的药ETF华宝标的指数日K、周K双双五连阴。图：港股通创新药ETF华宝近6月日K走势如何看待创新药本轮调整？低位埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvy5397470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1574","FLHK","159316","520880","BK1161","MEDX","06978","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667684278","title":"情緒冰點，A股單周成交額創年內新低！有色領跌，創新藥不振！關注華寶基金創業板人工智能ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2667684278","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667684278?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:24","pubTimestamp":1789298640,"startTime":"0","endTime":"0","summary":"本周，A股主要指数整体承压、多数收跌，创指逆市上涨1.08%一枝独秀，市场显著缩量，累计成交9.46万亿元，创年内单周地量，短期情绪或触冰点。资金关注高“光”指数布局机会，创业板人工智能ETF华宝场内热度高企，标的指数日内“V”型拉升。该规则已于7月22日通过，拟于9月11日在联邦公报正式刊载，30日后正式生效。三重因素扰动，有色ETF跳空下跌！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvw4446663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TECY","LCLG","QTOC","399006","MEDX","MVPS","000001.SH","CWC","399300","LNGR","NBDS","NEWZ","GK","159992","ARTY","06978","510300","IBBQ","OGIG","TARK","159915","FDN","AIBU","159967","WPAI","159876","AIFD","000688.SH","PBOT","QQA","CNXT","000300.SH","161631","FWD","VUSE","510880","AIQU","03188","159982","CHAT","DQJN","512510","QSWN","KOMP","MFIG","AGIX","AQGX","QID","CPNQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667681787","title":"從「產品出海」到「體系出海」，上海創新藥企復宏漢霖加速全球佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2667681787","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667681787?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 17:19","pubTimestamp":1789291195,"startTime":"0","endTime":"0","summary":"日前，上海创新药企复宏汉霖举办2026年开放日活动，围绕全球化布局、生物类似药商业化、创新研发及临床开发等话题披露最新进展。复宏汉霖执行董事、首席执行官朱俊博士介绍，截至目前，复宏汉霖已有4款产品获美国食品药品监督管理局（FDA）批准、5款获欧盟（EC）批准、8款获中国国家药品监督管理局（NMPA）批准，产品已惠及全球超过110万名患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872844911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872844911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1574","IBBQ","HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","HK0000306701.USD","BK1161","159992","06978","MEDX","02696"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":5,"totalSize":254,"code":"91000000","status":"200"}]}}